Ones To Watch News
Refine search
Biotechnology
US clinical-stage biotech Tyra Biosciences yesterday announced initial results from SURF302, its Phase II study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). 10 September 2026
Biotechnology
US biotech Evommune has said its oral MRGPRX2 antagonist EVO756 failed to meet its primary or secondary endpoints in a Phase IIb trial in moderate-to-severe atopic dermatitis (AD), and that it does not plan to advance the candidate further in the indication. 10 September 2026
Biotechnology
USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. 10 September 2026
Biotechnology
UK clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as chief medical officer (CMO) to accelerate the clinical development of the company’s pipeline of highly novel antibody therapeutics. 10 September 2026
Biotechnology
Netherlands-based Scenic Biotech, a company developing therapies that restore lysosomal function in neurodegenerative disease, has appointed Judith Walker as chief medical officer, as the firm prepares to move its lead program into the clinic in early 2027. 10 September 2026
Biotechnology
US clinical stage biotech Callio Therapeutics has announced the appointment of Zachary (Zach) Hornby as chief executive (CEO). 10 September 2026
Pharmaceutical
US biotech company TwoStep Therapeutics has secured Food and Drug Administration (FDA) clearance to begin human testing of its lead cancer candidate, TS-104, alongside an oversubscribed $62.5 million series A financing. The San Carlos, California-based firm said patient enrollment in a first-in-human Phase I trial should begin before the end of the year. 10 September 2026
Biotechnology
US biotech company Encoded Therapeutics has closed a $275 million series F financing that will fund pivotal testing of ETX101, a gene therapy for Dravet syndrome, a severe form of childhood epilepsy. The privately held South San Francisco firm announced the round on Wednesday, days after presenting updated trial data at the European Epilepsy Congress. 10 September 2026
Biotechnology
NodThera, the US biotech developing oral NLRP3 inhibitors, has renamed itself Rezera and announced plans to advance its lead candidate, ruvonoflast, into a Phase III trial in peripheral artery disease (PAD) in the first half of 2027, alongside positive topline data from a Phase II study of the drug. 9 September 2026
Biotechnology
US biotech Kura Oncology today announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. 9 September 2026
Pharmaceutical
An artificial intelligence reading of lung scans from a mid-stage trial of Endeavor BioMedicines' taladegib has found that the experimental drug improved the physical structure of the lungs in idiopathic pulmonary fibrosis (IPF), an effect its developers argue standard breathing tests capture only in part. 9 September 2026
Biotechnology
Swedish biologics company Simris Group has settled on amanitin as the basis of its antibody-drug conjugate work, and says it intends to take two proprietary programs into clinical development by late 2027 or early 2028. 9 September 2026
Pharmaceutical
US targeted cardiometabolic therapeutics company Sparrow Pharmaceuticals has announced the appointment of George Eldridge as chief financial officer (CFO). 9 September 2026
Biotechnology
US biopharma Inhibrx Biosciences has reported that its OX40 agonist INBRX-106, combined with Merck & Co's Keytruda (pembrolizumab) nearly doubled response rates against pembrolizumab alone in a randomized Phase II trial in head and neck squamous cell carcinoma (HNSCC). 9 September 2026
Pharmaceutical
New Jersey, USA-based precision oncology company PMV Pharmaceuticals today announced the appointment of Philip Herman as chief commercial officer (CCO). 9 September 2026
Biotechnology
US biotech Moonwalk Biosciences, which is developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an oversubscribed $70 million Series B financing. 8 September 2026
Biotechnology
US clinical-stage biotech PDS Biotechnology saw its shares rocket 183% to $0.62 today, after it announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (PIPE) transaction. 8 September 2026
Biotechnology
Germany-based contract development and manufacturing firm ProBioGen and French biotech Transgene announced that the companies have broadened the scope of their existing collaboration. 8 September 2026
Biotechnology
UK biotech Cytospire Therapeutics, which is developing differentiated multispecific immune cell engager antibodies, today announces the appointment of Dr Sumeet Ambarkhane as chief medical officer (CMO). 8 September 2026
Biotechnology
Australian late-stage biotech Neurizon Therapeutics today announced the appointment of Dr Chris Bremer as chief executive (CEO), effective October1, 2026. 7 September 2026
Biotechnology
Danish biotech company Muna Therapeutics has named Michel Detheux as chief executive as it prepares to move its lead Alzheimer’s disease candidate toward Phase II testing. 30 June 2026
Biotechnology
US biotech BioCryst Pharmaceuticals is winding down its internal drug discovery programs and plans to close its Discovery Center of Excellence in Birmingham, Alabama, by the end of 2026, as it shifts toward externally sourced rare disease assets. 30 June 2026
Biotechnology
Finnish clinical-stage biotech Aplagon has appointed pharmaceutical industry veteran Carl Lindgren as chair of its board of directors as the company prepares to advance its lead thrombo-inflammatory therapy into later-stage development. 30 June 2026
Biotechnology
Shares of US biotech Larimar Therapeutics closed down 16.5% at $3.06 yesterday, despite the company announcing the submission of the first module of its rolling Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the accelerated approval of nomlabofusp. 30 June 2026
Biotechnology
Evommune is ending development of EVO756 in chronic spontaneous urticaria after the oral MRGPRX2 antagonist failed a mid-stage trial, dealing a sharp setback to one of the company’s lead inflammatory disease programs. 30 June 2026
Biotechnology
US clinical-stage biotech Kailera Therapeutics, which is focused on elevating the next era of obesity care, has announced the appointment of Kathleen Tregoning as chief corporate affairs officer. 30 June 2026
Biotechnology
Talawar Tx, a biotech company developing potentially best-in-class bispecific antibodies that pair independent immunology and inflammatory (I&I) disease drivers, and JATT II Acquisition Corp, a special purpose acquisition company focused on building the next wave of life sciences companies, today announced they have entered into a definitive business combination agreement. 29 June 2026
Pharmaceutical
Lycia Therapeutics has raised $75 million in an oversubscribed series D financing to support clinical development of its extracellular protein degrader pipeline. 29 June 2026
Biotechnology
Canadian biotech Zymeworks today revealed it has entered into a definitive agreement to acquire USA-based Theravance Biopharm. The latter’s shares dipped 2.7% to $17.15 in pre-market activity on the news. 29 June 2026
Biotechnology
US biotech Viridian Therapeutics saw its shares climb more than 10% to $19.81 in after-hours activity Friday, when it revealed that the US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). 27 June 2026
Biotechnology
US clinical-stage biotech Elixirgen Therapeutics has entered into an option agreement with Japan’s Nippon Shinyaku. 26 June 2026
Pharmaceutical
US biopharma Definium Therapeutics has closed an upsized public offering that raised $805 million in gross proceeds, days after reporting positive Phase III data for its lead neuropsychiatric candidate, DT120 ODT. 26 June 2026
Biotechnology
Candel Therapeutics has appointed oncology commercial veteran Mark Sims as chief commercial officer, effective July 6, as the company prepares for the potential launch of its lead cancer immunotherapy, aglatimagene besadenovec (CAN-2409), for localized prostate cancer. 26 June 2026
Biotechnology
German drugmaker Merck KGaA said today it will acquire US biotech firm Bio-Techne Corp for $11.3 billion, expanding its presence in the life sciences market. The transaction marks the Merck’s largest acquisition in over a decade. 25 June 2026
Biotechnology
Texas, USA-based biotech Vaxxirna has announced its launch as an independent company dedicated to developing vaccines powered by its proprietary viRNA circular RNA platform. 25 June 2026
Biotechnology
US biotech Regenxbio has completed dosing in the confirmatory part of its AFFINITY DUCHENNE trial of RGX-202, keeping the company on course for a planned biologics license application (BLA) submission to the US Food and Drug Administration (FDA) in the third quarter of 2026. 25 June 2026
Biotechnology
US biotech Passage Bio has agreed an all-stock reverse merger with RNA specialist Remix Therapeutics, giving the private company a route onto Nasdaq and fresh capital to push its lead cancer candidate through key clinical readouts. 25 June 2026
Biotechnology
US clinical-stage biotech Ollin Biosciences has raised $330 million in an oversubscribed Series B round to fund global Phase III studies of OLN324, its lead retinal disease candidate. 24 June 2026
Biotechnology
In 2025, when Eli Lilly acquired Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program, Antares Therapeutics - a biotechnology company developing transformational, first-in-class precision medicines focused on validated, undruggable targets in cancer and other serious diseases with significant unmet need - was spun out of the deal with $177 million in Series A financing. 24 June 2026
Biotechnology
Danish biotech Combotope Therapeutics, which is focused on discovering tumor-selective antibodies against cancer-specific glycan–protein targets, announced a strategic research collaboration with Germany’s Boehringer Ingelheim. 24 June 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze